Skip to main content
SpringerLink
Log in

Palpitations in Athletes

  • Injury Clinic
  • Published:
Sports Medicine Aims and scope Submit manuscript

Abstract

In an athletic population, the incidence of palpitations varies from 0.3% to as high as 70%, depending on age and type of sport being studied. Palpitations, or an awareness of an increased or abnormal heart beat, are rare in the school-age athlete, but much more common in older endurance athletes. The majority are felt to be benign, with prognosis relating to type of specific rhythm disturbance and presence or absence of underlying heart disease.

Atrial fibrillation can account for up to 9% of rhythm disturbances in elite athletes, and up to 40% in those with long-standing symptoms. In athletes with premature ventricular beats (PVCs), underlying heart disease is more likely to be present in those with a high PVC burden, defined as ≥2000 PVCs/24 hours. Choice of monitoring device is crucial in making a proper diagnosis of the specific rhythm disturbance. For symptoms occurring within a 24-hour period, simple Holter monitoring is adequate to make a diagnosis. However, if symptoms occur less frequently, clinicians must choose one of the other available monitoring devices. Most importantly, choice of device should depend on which device is most likely to detect the rhythm disturbance. Other cardiac testing such as echocardiography, stress testing, endomyocardial biopsy, genetic testing, electrophysiologic testing, or cardiac magnetic resonance imaging may be indicated as well. The majority of palpitations in athletes will be first identified by screening examination, or by a complaint from the athlete. The third and most current preparticipation examination monograph recommends asking the athlete if he/she has palpitations with exercise.

The assumption has been made that palpitations occurring at rest in athletes are benign, but this theory has not been validated prospectively in a large cohort of the athletic population. Specific rhythms can often be treated with radiofrequency ablation, with return to sports provided there is no significant high risk underlying heart disease present. Athletes with known malignant ventricular rhythm disturbances, or underlying substrate for such, who have undergone implantation of an automatic implanted cardioverter-defibrillator are not recommended to return to sport because there is no data on the safety and efficacy of defibrillators in this clinical setting, and certain athletic activities may result in damage to the device.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

reference

  1. Glover DW, Maron BJ. Profile of preparticipation cardiovascular screening for high school athletes. JAMA 1998; 279:1817–9

    Article  PubMed  CAS  Google Scholar 

  2. Pfister GC, Puffer JC, Maron BJ. Preparticipation cardiovascular screening for US collegiate student-athletes. JAMA 2000; 283: 1597–9

    Article  PubMed  CAS  Google Scholar 

  3. Pellicia A, Maron BJ. Preparticipation cardiovascular evaluation of the competitive athlete: perspectives from the 30-year Italian experience. Am J Cardiol 1995; 75: 827–9

    Article  Google Scholar 

  4. Corrado D, Basso C, Schiavon M, et al. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998;339:364–9

    Article  PubMed  CAS  Google Scholar 

  5. Maron BJ, Zipes DP. 36th Bethesda Conference: eligibility recommendations for competitive athletes with cardiovascular abnormalities. J Am Coll Cardiol 2005; 45: 1–64

    Article  Google Scholar 

  6. Estes NA, Link MS, Cannom D, et al. Report of the NASPE policy conference on arrhythmias and the athlete. J Cardiovasc Electrophysiol 2001; 12: 1208–19

    Article  PubMed  Google Scholar 

  7. Maron BJ, Araujo CG, Thompson PD, et al. Recommendations for preparticipation screening and the assessment of cardiovascular disease in masters athletes: an advisory for healthcare professionals from the working groups of the World Heart Federation, the International Federation of Sports Medicine, and the American Heart Association Committee on Exercise,Cardiac Rehabilitation, and Prevention. Circulation 2001; 103:327–34

    Article  PubMed  CAS  Google Scholar 

  8. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004; 109(22): 2807–16

    Article  PubMed  Google Scholar 

  9. Weber BE, Kapoor WN. Evaluation and outcomes of patients with palpitations. Am J Med 1996; 100: 138–48

    Article  PubMed  CAS  Google Scholar 

  10. Fuller CM, McNulty CM, Spring DA, et al. Prospective screening of 5615 high school athletes for risk of sudden cardiac death. Med Sci Sports Exer 1997; 29: 1131–8

    Article  CAS  Google Scholar 

  11. Niwa K, Warita N, Sunami Y, et al. Prevalence of arrhythmias and conduction disturbances in large population-based samples of children. Cardiol Young 2004; 14: 68–74

    Article  PubMed  Google Scholar 

  12. Biffi A, Pelliccia A, Verdile L, et al. Long-term clinical significance of frequent and complex ventricular tachyarrhythmias in trained athletes. J Am Coll Cardiol 2002; 40: 446–52

    Article  PubMed  Google Scholar 

  13. Furlanello F, Bertoldi A, Dallago M, et al. Atrial fibrillation in elite athletes. J Cardiovasc Electrophysiol 1998; 9: S63–8

    PubMed  CAS  Google Scholar 

  14. Karjalainen J, Kujala UM, Kaprio J, et al. Lone atrial fibrillation in vigorously exercising middle-aged men: case control study.BMJ 1998; 316: 1784–5

    Article  PubMed  CAS  Google Scholar 

  15. Talan DA, Bauernfeind RA, Ashley WW, et al. Twenty-four hour continuous ECG recordings in long-distance runners.Chest 1982; 82: 19–24

    Article  PubMed  CAS  Google Scholar 

  16. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death. Circulation 2000; 102:858–64

    Article  PubMed  CAS  Google Scholar 

  17. Smith DM, Kovan JR, Rich BSE, et al. Preparticipation physical evaluation. 2nd ed. Minneapolis (MN): McGraw-Hill, 1997:1–46

    Google Scholar 

  18. Preparticipation physical evaluation. 3rd ed. Minneapolis (MN): McGraw-Hill/The Physician and Sports-Medicine, 2005

  19. Foote CB, Michaud G. The athletes ECG: distinguishing normal from abnormal. In: Estes NA, Salem D, Wang PJ, editors.Sudden cardiac death in the athlete. Armonk (NY): Futura,1998: 101–14

    Google Scholar 

  20. Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long Q-T syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 2001; 103:89–95

    Article  PubMed  CAS  Google Scholar 

  21. Barsky AJ. Palpitations, cardiac awareness, and panic disorder.Am J Med 1992; 92: 31–4S

    Article  Google Scholar 

  22. Barsky AJ, Cleary PD, Coeytaux RR, et al. Psychiatric disorders Med 1994; 9: 306–13

    CAS  Google Scholar 

  23. Witchel HJ, Hancox JC, Nutt D. Psychotrophic drugs, cardiac arrythmia, and sudden death. J Clin Psychopharmacol 2003;23: 58–77

    Article  PubMed  CAS  Google Scholar 

  24. Knudsen MP. The natural history of palpitations in a family practice. J Fam Pract 1987; 24: 357–60

    Google Scholar 

  25. Biffi A, Maron BJ, Verdile L, et al. Impact of physical decondtioning on ventricular tachyarrhythmias in trained athletes. JAm Coll Cardiol 2004; 44: 1053–8

    Article  Google Scholar 

  26. Kinlay S, Leitch JW, Neil A, et al. Cardiac event recorders yield more diagnoses and are more cost-effective than 48 hour Holter monitoring in patients with palpitations: a controlled clinical trial. Ann Intern Med 1996; 124: 16–20

    PubMed  CAS  Google Scholar 

  27. Fogel RI, Evans JJ, Prystowsky EN. Utility and cost of event recorders in the diagnosis of palpitations, presyncope and syncope. Am J Cardiol 1997; 79: 207–8

    Article  PubMed  CAS  Google Scholar 

  28. Zimetbaum PJ, Josephson ME. The evolving role of ambulatory arrhythmia monitoring in general clinical practice. Ann Intern Med 1999; 130: 848–56

    PubMed  CAS  Google Scholar 

  29. Krahn AD, Klein GJ, Yee R, et al., for the Reveal Investigators. Use of an extended monitoring strategy in patients with problematic syncope. Circulation 1999; 99: 406–10

    Article  PubMed  CAS  Google Scholar 

  30. Maron BJ, Barry J, Mitten MJ, et al. Competitive athletes with cardiovascular disease: the case of Nicholas Knapp. N Engl J Med 1998; 339(22): 1632–5

    Article  PubMed  CAS  Google Scholar 

  31. Krahn AD, Yee R, Klein GJ, et al. Inappropriate sinus tachycardia: evaluation and therapy. J Cardiovasc Electrophysiol 1995;6: 1124–8

    Article  PubMed  CAS  Google Scholar 

  32. Shen WK. How to manage patients with inappropriate sinus tachycardia. Heart Rhythm 2005; 2(9): 1015–9

    Article  PubMed  Google Scholar 

  33. Samenuk D, Link MS, Hamoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine. Mayo Clinic Proc 2002; 77: 12–6

    Article  Google Scholar 

  34. Estes NA, Kloner R, Olshansky B, et al. Task Force 9: drugs and performance-enhancing substances. J Am Coll Cardiol 2005;45(8): 1368–9

    Article  PubMed  Google Scholar 

  35. Furlanello F, Bentivegna S, Cappato R, et al. Arrhythmogenic effects of illicit drugs in athletes. Ital Heart J 2003; 4(12):829–37

    PubMed  Google Scholar 

  36. McLeod KA.Dizziness and syncope in adolescence. Heart 2001; 86: 350–4

    PubMed  CAS  Google Scholar 

  37. Stewert JM, Gewitz MH, Weldon A, et al. Orthostatic intolerance in adolescent chronic fatigue syndrome. Pediatrics 1999;103: 116–21

    Article  Google Scholar 

  38. Fischer B, Haissaguerre M, Garrigues S, et al. Radiofrequency catheter ablation of common atrial flutter in 80 patients. J Am Coll Cardiol 1995; 25: 1365–72

    Article  PubMed  CAS  Google Scholar 

  39. Hoogsteen J, Schep G, Van Hemel NM, et al. Paroxysmal atrial fibrillation in male endurance athletes: a 9-year follow up. Europace 2004; 6(3): 222–8

    Article  PubMed  Google Scholar 

  40. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339: 659–66

    Article  PubMed  CAS  Google Scholar 

  41. Haissaguerre M, Jais P, Shah DC, et al. Electrophysiological endpoint for catheter ablation of atrial fibrillation of atrial fibrillation initiated from multiple pulmonary venous foci. Circulation 2000; 101: 1409–17

    Article  PubMed  CAS  Google Scholar 

  42. Naccarelli GV, Shih H, Jalal S. Catheter ablation for the treatment of paroxysmal supraventricular tachycardia. J Cardiovasc Electrophysiol 1995; 6: 951–61

    Article  PubMed  CAS  Google Scholar 

  43. Calkins H, Yong P, Miller JM, et al. Catheter ablation of accessory pathways, atrioventricular nodal reentry tachycardia, and the atrioventricular junction: final results of a prospective, multicenter clinical trial. Circulation 1999; 99: 262–70

    Article  PubMed  CAS  Google Scholar 

  44. Klein GJ, Bashore TM, Sellers TD, et al. Ventricular fibrillationin the Wolff-Parkinson-White syndrome. N Engl J Med 1979;301: 1080–5

    Article  PubMed  CAS  Google Scholar 

  45. Nogami A. Idiopathic left ventricular tachycardia: assessment and treatment. Cardiac Electrophysiol Rev 2002; 6: 448–57

    Article  Google Scholar 

  46. Cole CR, Marrouche NF, Natale A. Evaluation and management of ventricular outflow tract tachycardias. cardiac electrophysiology review 2002; 6: 442–7

    Article  PubMed  Google Scholar 

  47. Lerman BB, Stein KM, Markowitz SM, et al. Ventricular arrhythmias in normal hearts. Cardiol Clin 2000; 18(2): 265–91

    Article  PubMed  CAS  Google Scholar 

  48. Ouyang F, Cappato R, Ernst S, et al. Electroanatomic substrate of idiopathic left ventricular tachycardia. Circulation 2002;105: 462–9

    Article  PubMed  Google Scholar 

  49. Maruyama M, Tadera T, Miyamoto S, et al. Demonstration of the reentrant circuit of verapamil-sensitive idiopathic left vetricular tachycardia: direct evidence for macroreentry as the underlying mechanism. J Cardiovasc Electrophysiol 2001; 12:968–72

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used in the preparation of this review and the authors have no conflicts of interest relevant to its contents.

Author information

Authors and Affiliations

  1. The Ohio State University Medical Center, Columbus, Ohio, USA

    Christine E. Lawless

  2. Lutheran General Hospital, Park Ridge, Illinois, USA

    William Briner

Authors
  1. Christine E. Lawless
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William Briner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine E. Lawless.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lawless, C.E., Briner, W. Palpitations in Athletes. Sports Med 38, 687–702 (2008). https://doi.org/10.2165/00007256-200838080-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00007256-200838080-00006

Keywords

Search

Navigation